344 related articles for article (PubMed ID: 35462012)
1. Developing patient-derived organoids to predict PARP inhibitor response and explore resistance overcoming strategies in ovarian cancer.
Tao M; Sun F; Wang J; Wang Y; Zhu H; Chen M; Liu L; Liu L; Lin H; Wu X
Pharmacol Res; 2022 May; 179():106232. PubMed ID: 35462012
[TBL] [Abstract][Full Text] [Related]
2. The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testing.
Tao M; Wu X
J Exp Clin Cancer Res; 2021 Oct; 40(1):338. PubMed ID: 34702316
[TBL] [Abstract][Full Text] [Related]
3. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
[TBL] [Abstract][Full Text] [Related]
4. Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance.
Serra V; Wang AT; Castroviejo-Bermejo M; Polanska UM; Palafox M; Herencia-Ropero A; Jones GN; Lai Z; Armenia J; Michopoulos F; Llop-Guevara A; Brough R; Gulati A; Pettitt SJ; Bulusu KC; Nikkilä J; Wilson Z; Hughes A; Wijnhoven PWG; Ahmed A; Bruna A; Gris-Oliver A; Guzman M; Rodríguez O; Grueso J; Arribas J; Cortés J; Saura C; Lau A; Critchlow S; Dougherty B; Caldas C; Mills GB; Barrett JC; Forment JV; Cadogan E; Lord CJ; Cruz C; Balmaña J; O'Connor MJ
Clin Cancer Res; 2022 Oct; 28(20):4536-4550. PubMed ID: 35921524
[TBL] [Abstract][Full Text] [Related]
5. Genomic and expressional dynamics of ovarian cancer cell lines in PARPi treatment revealed mechanisms of acquired resistance.
Cheng A; Rao Q; Liu Y; Huang C; Li J; Huo C; Lin Z; Lu H
Gynecol Oncol; 2022 Dec; 167(3):502-512. PubMed ID: 36270832
[TBL] [Abstract][Full Text] [Related]
6. PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies.
Miller RE; El-Shakankery KH; Lee JY
J Gynecol Oncol; 2022 May; 33(3):e44. PubMed ID: 35320891
[TBL] [Abstract][Full Text] [Related]
7. Resistance to Poly (ADP-Ribose) Polymerase Inhibitors (PARPi): Mechanisms and Potential to Reverse.
Washington CR; Moore KN
Curr Oncol Rep; 2022 Dec; 24(12):1685-1693. PubMed ID: 36346509
[TBL] [Abstract][Full Text] [Related]
8. Poly(ADP-Ribose) Polymerase Inhibitor Inhibition in Ovarian Cancer: A Comprehensive Review.
Moore KN; Pothuri B
Cancer J; 2021 Nov-Dec 01; 27(6):432-440. PubMed ID: 34904806
[TBL] [Abstract][Full Text] [Related]
9. Distinct roles of treatment schemes and BRCA2 on the restoration of homologous recombination DNA repair and PARP inhibitor resistance in ovarian cancer.
Huang TT; Burkett SS; Tandon M; Yamamoto TM; Gupta N; Bitler BG; Lee JM; Nair JR
Oncogene; 2022 Nov; 41(46):5020-5031. PubMed ID: 36224341
[TBL] [Abstract][Full Text] [Related]
10. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
[TBL] [Abstract][Full Text] [Related]
11. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models.
Kim H; Xu H; George E; Hallberg D; Kumar S; Jagannathan V; Medvedev S; Kinose Y; Devins K; Verma P; Ly K; Wang Y; Greenberg RA; Schwartz L; Johnson N; Scharpf RB; Mills GB; Zhang R; Velculescu VE; Brown EJ; Simpkins F
Nat Commun; 2020 Jul; 11(1):3726. PubMed ID: 32709856
[TBL] [Abstract][Full Text] [Related]
12. Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
Sheta R; Bachvarova M; Plante M; Renaud MC; Sebastianelli A; Gregoire J; Navarro JM; Perez RB; Masson JY; Bachvarov D
J Transl Med; 2020 Nov; 18(1):439. PubMed ID: 33213473
[TBL] [Abstract][Full Text] [Related]
13. Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors.
Lee EK; Matulonis UA
Expert Opin Emerg Drugs; 2020 Jun; 25(2):165-188. PubMed ID: 32569489
[TBL] [Abstract][Full Text] [Related]
14. PARP1-DOT1L transcription axis drives acquired resistance to PARP inhibitor in ovarian cancer.
Liu C; Li J; Xu F; Chen L; Ni M; Wu J; Zhao H; Wu Y; Li J; Wu X; Chen X
Mol Cancer; 2024 May; 23(1):111. PubMed ID: 38778348
[TBL] [Abstract][Full Text] [Related]
15. RAD51D Secondary Mutation-Mediated Resistance to PARP-Inhibitor-Based Therapy in HGSOC.
Xu J; Dai Y; Gao Y; Chai R; Lu C; Yu B; Kang Y; Xu C
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833926
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of PARP Inhibitor Resistance.
O'Connor MJ; Forment JV
Cancer Treat Res; 2023; 186():25-42. PubMed ID: 37978129
[TBL] [Abstract][Full Text] [Related]
17. The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma.
Morra F; Merolla F; Damia G; Ricci F; Varricchio S; Ilardi G; Arenare L; Califano D; Napolitano V; Fruscio R; Melillo RM; Palazzo L; Celetti A
J Exp Clin Cancer Res; 2022 Aug; 41(1):245. PubMed ID: 35964058
[TBL] [Abstract][Full Text] [Related]
18. Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer.
Chiappa M; Guffanti F; Bertoni F; Colombo I; Damia G
Drug Resist Updat; 2021 Mar; 55():100744. PubMed ID: 33551306
[TBL] [Abstract][Full Text] [Related]
19. Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.
Pellegrino B; Herencia-Ropero A; Llop-Guevara A; Pedretti F; Moles-Fernández A; Viaplana C; Villacampa G; Guzmán M; Rodríguez O; Grueso J; Jiménez J; Arenas EJ; Degasperi A; Dias JML; Forment JV; O'Connor MJ; Déas O; Cairo S; Zhou Y; Musolino A; Caldas C; Nik-Zainal S; Clarke RB; Nuciforo P; Díez O; Serres-Créixams X; Peg V; Espinosa-Bravo M; Macarulla T; Oaknin A; Mateo J; Arribas J; Dienstmann R; Bellet M; Oliveira M; Saura C; Gutiérrez-Enríquez S; Balmaña J; Serra V
Cancer Res; 2022 Apr; 82(8):1646-1657. PubMed ID: 35425960
[TBL] [Abstract][Full Text] [Related]
20. Platinum Resistance After PARPi Resistance in a gBRCAmt Recurrent Ovarian Cancer Patient: a Case Report.
Zhao Q; Ni J; Dong J; Cheng X; Xiao L; Xue Q; Xu X; Guo W; Chen X
Reprod Sci; 2023 Feb; 30(2):615-621. PubMed ID: 35943701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
